QPPV.COM KNOWLEDGE ASSESSMENT

Talquetamab Classification, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Talquetamab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which periodic benefit-risk approach best reflects the article's recommendations?

Focus exclusively on grade 3 or 4 events and formally serious cases Assess myeloma benefit alongside CRS, neurological toxicity, infection, hypogammaglobulinaemia, cytopenias and cumulative oral, nutritional, skin and nail burden Evaluate only the frequency of dysgeusia because it is the product's defining risk Exclude patient-reported functional effects unless they lead to hospitalisation

Question 2 of 10 Which description best captures talquetamab's pharmacological mechanism?

A monoclonal antibody that blocks BCMA-mediated plasma-cell survival A bispecific antibody that links GPRC5D-expressing cells to CD3-positive T cells A small molecule that inhibits cytokine release by activated T cells An antibody-drug conjugate that delivers cytotoxic drug directly to CD3-positive cells

Question 3 of 10 What is the best reason to record nail findings separately from a nonspecific rash term?

Nail findings have no clinical relevance and should be excluded Nail phenotype can provide target-specific information and may have functional or treatment-related consequences Nail changes are diagnostic of CRS A rash term is always more precise than a nail diagnosis

Question 4 of 10 Which factor most complicates attribution of infection and cytopenia in talquetamab-treated patients?

Patients generally have no prior treatment exposure The treatment population commonly has advanced disease, marrow dysfunction and cumulative immune injury Talquetamab is administered only once in a patient's lifetime GPRC5D is expressed exclusively in bacteria

Question 5 of 10 What does talquetamab's conditional EU marketing authorisation and additional-monitoring status imply?

The medicine has no demonstrated clinical activity The authorisation is supported by less comprehensive evidence than a standard authorisation and requires continuing evidence generation and safety characterisation All adverse events must be considered unexpected The product may be used without reference to current product information

Question 6 of 10 Which adverse-event pattern is most characteristic of GPRC5D-directed treatment rather than a general CD3-engagement effect?

Cytokine release syndrome alone Dysgeusia accompanied by oral symptoms, nail changes and nutritional effects Transient fever with no other findings A decrease in tumour burden

Question 7 of 10 What is the principal pharmacovigilance significance of talquetamab's IgG4-PAA classification?

It establishes that the product is a full-length biological with two antigen specificities It proves that the product cannot activate T cells It means that the product is chemically identical to a small-molecule immunomodulator It indicates that the product targets only normal epithelial tissues

Question 8 of 10 Why is GPRC5D pharmacologically important as an alternative tumour-side target to BCMA?

GPRC5D is expressed only on T cells and therefore avoids tumour-antigen variability GPRC5D targeting creates a distinct antigenic strategy that may remain relevant after prior BCMA-directed treatment GPRC5D is a soluble plasma protein that prevents immune-cell activation GPRC5D targeting eliminates the need for CD3 engagement

Question 9 of 10 Which combination provides the strongest mechanistic context for talquetamab-associated weight loss?

Weight loss alone with no information about intake or symptoms Dysgeusia, oral symptoms or dysphagia, reduced intake and a documented longitudinal decline in weight A single low body weight measurement before treatment Weight loss occurring only after a documented bacterial infection

Question 10 of 10 What is the primary pharmacovigilance purpose of step-up dosing?

To eliminate the need for monitoring during the first treatment doses To reduce the abruptness of initial T-cell activation and allow enhanced observation for acute toxicity To ensure that GPRC5D expression is increased before every dose To prevent all infections during subsequent treatment

Talquetamab Classification, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings